Virtuelle Messe

ECCVID 2020

September 23 - 25, 2020

Online

France

Description

ESCMID Conference on Coronavirus Disease (ECCVID)

The ESCMID Conference on Coronavirus Disease (ECCVID) will take place online from Wednesday 23rd to Friday 25th September 2020 and will cover all aspects of COVID-19. ECCVID will feature a comprehensive scientific program that will span a wide range of topics surrounding this emerging threat. We are learning continually about the new SARS-CoV-2 virus and an international scientific event that brings together the latest research and scientific evidence is very timely. ECCVID will offer excellent opportunities to showcase the latest findings, share experiences and knowledge and demonstrate practical techniques and guidance. Internationally renowned clinical microbiologists, infectious diseases specialists and experts from related disciplines will present their work and latest findings on COVID-19, during the event.

Venue: Online at www.eccvid.org

Confirmed scientific program

Please join our talks and panel discussion where the audience can pose their questions to the speakers.

 

Recognizing the Immune Response to SARS-CoV-2 

Andrea Cossarizza, M.D., Ph.D, Chair of Pathology and Immunology, University of Modena and Reggio Emilia, IT

Thursday, Sept. 24 • 17:15-18:15 h (CEST)

The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a great challenge to the human health worldwide, with millions of infections. We were immediately involved in studying the role of immune system in fighting SARS-CoV2, and have focused our attention on T lymphocytes, B cells and monocytes to investigate the mechanisms underlying the progressive leukopenia observed in patients.
Multiparameter flow cytometry, coupled with unsupervised data analysis, allowed us to find that the T cell compartment in COVID-19 patients with severe pneumonia has several alterations that involve naïve, central memory, effector memory and terminally differentiated cells, as well as regulatory T cells and PD1+CD57+ exhausted T cells. Several lineage-specifying transcription factors and chemokine receptors are also altered. Terminally differentiated T cells from patients proliferate less than those from healthy controls, whereas their mitochondria functionality is similar in CD4+ T cells from both groups. Dramatic simultaneous increases of proinflammatory or anti-inflammatory cytokines, including T helper type-1 and type-2 cytokines, chemokines and galectins were observed in plasma.
We then interrogated B cells in these patients, who displayed normal plasma level of the main immunoglobulin classes, of antibodies against common antigens or against antigens present in common vaccines. A decreased number of total and naïve B cells was found, along with decreased percentages and numbers of memory switched and unswitched B cells. On the contrary, IgM+ and IgM- plasmablasts were significantly increased. In vitro cell activation revealed that B lymphocytes showed a normal proliferation index and number of dividing cells per cycle.
Finally, the analysis of monocytes revealed a consistent redistribution of their subsets, with a significant expansion of intermediate/pro-inflammatory cells, a concomitant compression of classical monocytes, and an increased expression of inhibitory checkpoints, including PD-1/PD-L1. Altered bioenergetics and mitochondrial dysfunction was found, that included a reduced basal and maximal respiration, reduced spare respiratory capacity and decreased proton leak.

 

Automated group testing at scale to enable COVID-19 decision makers

Dr. Nikhil Gopalkrishnan, and Dr. Josie Kishi, Wyss Institute, US

Thursday, Sept. 24 • 17:15-18:15 h (CEST)

Large scale testing is essential for comprehensive tracking of pathogens such as COVID-19 as they spread through a population. But scaling up testing may be limited by reagent cost and labor time. Here, we present our work to 1) streamline one step in this process by using an Echo acoustic liquid handler to rapidly and automatically pool hundreds to thousands of samples together into dozens of reactions in a matter of minutes and 2) deconvolute results to retrieve patient-specific testing results using Tapestry-based algorithms. Combined, these developments could enable rapid and inexpensive high throughput testing at the population scale.